Comparison of the immune profile of MS-RR subjects categorized according to the therapy they undergo (fingolimod vs. all treatment except fingolimod) revealed significant changes in circulating T-cell number and percentage, CD4/CD8 ratio, iNKT, B cell number, and NK percentage (Figure 2). This evidence concerns the gene CD4 and myeloid sarcoma.